A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 1927-1932

  Kayani, Irfan ^a   Conry, Brendon G ^a   Groves, Ashley M ^a   Win, Thida ^b   Dickson, John ^a   Caplin, Martyn ^c   Bomanji, Jamshed B ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

18F FDG; 68Ga DOTATATE; Neuroendocrine; PET CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID PHENYLALANINE 1 TYROSINE 3 OCTREOTATE GA 68; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; CANCER PATIENT; CANCER SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG EFFICACY; DRUG UPTAKE; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; LUNG TUMOR; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RECEPTOR AFFINITY; SMALL CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 73349102167     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066639     Document Type: Article

References (22)

1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-1068.
2. Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg. 2006;18:191-198.
3. Warren WH, Welker M, Gattuso P. Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors. Semin Thorac Cardiovasc Surg. 2006;18:199-205.
4. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR. 1998;170:1369-1373.
5. 68Ga DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
6. 68Ga-DOTATATE (DOTA-DPhe(1),Tyr(3)-octreotate) and 18F-FDG. Cancer. 2008;112:2447-2455.
7. 68Ga-DOTATyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
8. 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
9. Kruger S, Buck AK, Blumstein NM, et al. Use of integrated PET/CT imaging in pulmonary carcinoid tumors. J Intern Med. 2006;260:545-550.
10. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255-260.
11. Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors; diagnostic and prognostic implications. AJR. 2007;188:1223-1231.
12. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969-5977.
13. Srirajaskanthan R, Toumpanakis C, Karpathakis A, et al. Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer. 2008;65:68-73.
14. Chong S, Lee KS, Chung MY, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathological and imaging findings. Radiographics. 2006;26:41-57.
15. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593-597.
16. Gámez C, Rosell R, Fernández A, et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. J Thorac Oncol. 2006;1:74-77.
17. Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax. 2007;62:248-252.
18. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993.
19. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl):62S-66S.
20. 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34:1219-1227.
21. Laitinen KL, Soini Y, Mattila J, Pääkkö P. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer. 2000;88:1590-1598.
22. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221-232.